ELAV like RNA binding protein 1Genealiases: ELAV1 · HUR · Hua · MelG
Q-omics provides the consensus-scored ELAVL1 profile across patient tissues and cancer cell-line models. ELAVL1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ELAVL1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, ELAVL1 protein abundance shows 31,404 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, COAD, and LSCC as cancer lineages where ELAVL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELAVL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELAVL1 survival associations across molecular data types. ELAVL1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELAVL1 RNA expression–survival associations across cancer types. High ELAVL1 expression shows unfavorable associations in MESO, ACC, LGG and KIRP, but favorable associations in KIRC and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ELAVL1 RNA expression.
This table summarizes ELAVL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ELAVL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELAVL1 shows higher tumor expression in COAD, BLCA, HNSC, KIRP, LIHC and STAD. The COAD box plot shows higher ELAVL1 RNA expression in tumor versus normal tissue (log2 FC = +0.876, t-test p < 0.001).
This table shows molecular features associated with ELAVL1 in patient tissues and cancer cell lines. In patient samples, ELAVL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ELAVL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
